340B Drug Pricing Program
The American Hospital Association’s 2019 Public Policy Advocacy Agenda seeks to continue to positively influence the public policy environment for patients, communities and the health care field. We will work hand in hand with our members; the state, regional and metropolitan hospital associations…
On Dec. 27, the District Court for the District of Columbia issued an order in favor of the AHA and the other plaintiffs in the lawsuit to stop the Centers for Medicare & Medicaid Services' nearly 30 percent reduction in the reimbursement rate for 340B drugs as exceeding the statutory authority…
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
AHA commends the Centers for Medicare & Medicaid Services' willingness to address excessive growth in drug prices, but urges CMS to consider narrowing the scope of the program.
A federal judge today ruled in favor of the AHA and hospital plaintiffs saying that the Department of Health and Human Services “adjustment” by nearly 30 percent of 2018 Medicare payment rates for many hospitals in the 340B Drug Pricing Program was unlawful.
Dec. 27, 2018 court decision in 340B payment case
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program.
The Department of Health and Human Services today issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.